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Introduction
Osteoarthritis (OA) is the joint disease with the highest 
incidence. Th e disease is in general divided into primary 
OA and secondary OA. Primary OA has no obvious 
trigger, while secondary OA is the result of an evident 
underlying aﬄ  iction. Th e main features of this disease are 
cartilage erosion, synovial ﬁ brosis, osteophyte formation 
at the joint margins and sclerosis of the subchondral 
bone. Patients with OA suﬀ er from joint pain and tender-
ness, occasional eﬀ usions and, in the long run, loss of 
joint function.
Th e etiology of primary OA is not known but several 
risk factors have been detected. Systemic risk factors 
include genetic background, ethnicity, gender and obesity, 
but the main risk factor for the initiation and progression 
of primary OA is ageing. Functional articular cartilage is 
maintained by the cartilage cells, chondrocytes. Changes 
in chondrocytes, leading to the inability of these cells to 
maintain the homeostasis of articular cartilage, can be 
expected to be at the root of OA development. In view of 
the fact that the principal risk factor of OA is ageing, age-
related changes in chondrocytes are likely to be involved 
in OA development.
Changes in osteoarthritic chondrocytes
Cartilage is, on a weight basis, mainly composed of colla-
gens and proteoglycans. Collagens – for the most part type 
II, type IX and type XI – provide tensile strength, while the 
proteoglycan aggrecan retains water in the matrix. In 
humans, cartilage is composed of three zones: superﬁ cial 
zone, middle zone and deep zone. Th e superﬁ cial zone 
contains disc-shaped chondrocytes, the cells in the middle 
zone cells are more spherical and the deep zone contains 
spherical chondrocytes arranged in columns.
Cartilage damage in OA has several characteristics. At 
the initial stages of OA the cartilage surface is intact but 
focal edema and minor ﬁ brillations can be observed. 
Subse quently the superﬁ cial zone becomes ﬁ brillated 
and chondrocytes are lost from this zone. Finally, 
ﬁ brillations progress into ﬁ ssures – a process that is 
followed by cartilage erosion, denudation of bone and 
joint deformation.
At the initial stages of OA, chondrocytes start to 
multiply and form multicellular clusters. In addition, 
chondro cytes expressing markers of hypertrophic 
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chondro cytes are found in OA cartilage. A subpopulation 
of OA chondrocytes synthesizes molecules that, under 
normal conditions, are only expressed by terminally 
diﬀ er entiated (hypertrophic) chondrocytes, normally 
found in growth plates. Expression of osteocalcin, alka-
line phosphatase, c-maf, Runx2 and type X collagen has 
been demonstrated in OA chondrocytes [1-5]. Moreover, 
chondrocytes in OA cartilage express high levels of 
matrix metalloproteinase 13 (MMP-13), the enzyme 
most potently degrading type II collagen [6]. Th is under-
scores the hypertrophy-like character of OA chondro cytes 
since MMP-13 is highly upregulated during chondrocyte 
terminal diﬀ erentiation, and deﬁ ciency of MMP-13 even 
results in impaired endochondral ossiﬁ cation [7,8].
During OA, cartilage matrix degradation exceeds 
matrix deposition resulting in net matrix loss. In contrast 
to what is observed in inﬂ ammatory arthritis, mRNA 
expression and synthesis of a number of matrix molecules 
is increased instead of decreased compared with normal 
cartilage [9,10]. Only in the very late stages of OA does 
synthesis of matrix molecules drop below control levels. 
Th e synthesis of the main structural component of carti-
lage, type II collagen, is clearly enhanced in OA cartilage 
[11,12]. In OA cartilage, both catabolism (for example, 
MMP-13 synthesis) and anabolism (type II collagen 
synthesis) are high. It is unclear whether elevated 
catabolism and enhanced anabolism is achieved by the 
same cells or by diﬀ erent chondrocyte subpopulations.
Catabolic cytokines
Catabolic cytokines have been suggested to play a 
dominant role in OA. Chondrocytes can be stimulated by 
catabolic cytokines to release cartilage degradation 
products, ultimately leading to damage. A cytokine that 
is suggested to be a principle mediator of joint damage in 
OA is IL-1. Chondrocytes from OA cartilage display high 
levels of IL-1α and IL-1β and have elevated expression of 
the plasma membrane-bound IL-1 receptor I, while the 
decoy IL-1 receptor II is downregulated in OA chondro-
cytes [13]. Not only do ﬁ brillated areas show these 
expression patterns, but also cartilage proximal to 
macroscopic OA lesions demon strates a higher binding 
of TNFα and IL-1β com pared with chondrocytes from 
morphologically normal cartilage in the same joint [14]. 
Th is indicates not only that the levels of IL-1 are 
increased in OA joints, but also that OA chondro cytes 
are more sensitive to IL-1.
IL-1 is considered a principle mediator of joint damage 
in OA. IL-1 has the ability to stimulate chondrocytes to 
degrade both aggrecan and collagen [15]. Th is cytokine 
causes destruction of cartilage by increasing enzyme 
activity while decreasing the synthesis of enzyme inhibi-
tors [16]. IL-1 can stimulate chondrocytes to produce nitric 
oxide [17], matrix metalloproteinases [18] and aggrecanases 
(ADAMTS) [19], and suppresses the synthesis of aggrecan 
and collagen type II [20-22].
Th e latter is remarkable if IL-1 plays a dominant role in 
OA pathophysiology. IL-1 is a potent inhibitor of chondro-
cyte type II collagen synthesis, but type II collagen 
synthesis is increased during OA as discussed above. Th is 
discrepancy points to alternative players that are involved 
in OA. IL-1 might play a role in the induction of enzyme 
expression but is unlikely to be the only factor that deter-
mines development and progression of OA.
Osteoarthritic chondrocytes also express, besides cata-
bolic factors, anabolic factors such as transforming 
growth factor beta (TGFβ) [23,24]. Increased synthetic 
activity in early OA has been found to be accompanied 
with an upregulation of TGFβ expression [25,26]. We 
propose a role for TGFβ not only as a cartilage protective 
agent but also as a mediator of cartilage degeneration 
during ageing and OA development.
Transforming growth factor beta
Th e TGFβ superfamily is composed of over 35 members. 
Th e family members play fundamental roles in develop-
ment and homeostasis. In mammals, three isotypes of 
TGFβ are found: β1, β2 and β3. Expression of these three 
isoforms is diﬀ erently regulated at the transcriptional 
level due to dissimilar promoter sequences [27].
TGFβ is secreted as an inactive complex and requires 
activation before it is able to bind to its receptor [28]. 
Activated TGFβ binds to the TGFβ type II receptor and 
forms a complex that recruits the TGFβ type I receptor, 
ALK5. TGFβ has also recently been shown, however, to 
have the ability to signal via the alternative TGFβ type I 
receptor ALK1 in chondrocytes. In endothelial cells, but 
also in chondro cytes, activation of the ALK5 route is 
followed by Smad2 or Smad3 phosphorylation while 
ALK1 has been found to result in phosphorylation of 
Smad1, Smad5, or Smad8 [29-31]. Th e activated 
receptor Smads form a complex with the co-Smad, 
Smad4 – this complex translocates to the nucleus and 
modiﬁ es gene expression. Interestingly, signaling via 
either ALK5 or ALK1 can determine the response of 
cells to TGFβ stimulation, which can be totally contrary 
[32,33]. For example, in endothelial cells ALK5 inhibits 
migration whereas ALK1 stimulates migration and 
proliferation [34].
Signaling via the Smad pathway appears to be the most 
important signaling pathway for TGFβ, but this is not the 
only pathway. Mitogen-activated protein kinase, Rho-like 
GTPase and phopshatidylinositol-3-kinase pathways are 
involved in TGFβ signaling (reviewed in [35]). Activation 
of TGFβ activated kinase 1 occurs independent of ALK5 
kinase activity and results in P38 and JNK signaling [36]. 
Th at TGFβ activates diﬀ erent pathways calls attention to 
the fact that one has to take into account the diﬀ erences 
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in management of the TGFβ signal in diﬀ erent cell types 
and the subsequent variation in TGFβ eﬀ ects.
Transforming growth factor beta and osteoarthritis
Family studies have indicated a relation between TGFβ 
and a disease related to OA. In Japanese women a poly-
morphism of TGFβ1 on position 29 (T to C, amino acid 10) 
positioned in the signal sequence region of TGFβ1 is 
related to an elevated prevalence of spinal osteophytosis and 
ossiﬁ cation of the posterior longitudinal ligament [37,38].
Asporin inhibits TGFβ-mediated expression of cartilage 
matrix genes such as collagen type II and aggrecan, and 
inhibits accumulation of proteoglycan [39]. Kizawa and 
colleagues found an asporin polymorphism that showed 
a signiﬁ cantly higher frequency in OA [39]. Th e D-14 
polymorphism had a stronger inhibitory eﬀ ect on TGFβ 
than the common D-13 repeat. Th is indicates that 
expression of D-14 results in strong TGFβ inhibition and 
that this is associated with OA development. When this 
study was repeated in a Spanish Caucasian population by 
Rodriguez-Lopez and colleagues, however, the higher 
susceptibility to OA of people with the D-14 polymor-
phism was not found [40]. In a subset of UK Caucasians, 
a trend was seen towards a higher degree of D-14 poly-
morphism in OA. In a diﬀ erent ethnic group of Asian 
origin, Han Chinese, the OA susceptibility was again 
found [41]. Th ese studies indicate that reduced TGFβ 
signal ing can result in OA development.
Mice deﬁ cient for Smad3 developed degenerative joint 
disease resembling human OA. Chondrocytes present in 
the articular cartilage of Smad3-deﬁ cient mice showed 
enhanced chondrocyte hypertrophy indicated by increased 
expression of type X collagen. Th ese data indicate that 
Smad3 signaling is essential for repressing chondrocyte 
terminal diﬀ erentiation. Th is observation is supported by 
studies in mice that overexpress a dominant-negative 
TGFβ type II receptor in skeletal tissues [42]. Th ese mice 
developed progressive skeletal degeneration that strongly 
resembles human OA. In addition, mice that lack latent 
TGFβ binding protein 3 also show altered chondrocyte 
diﬀ erentiation and early OA development [43,44]. 
Interference with normal TGFβ signaling apparently 
results in aberrations in chondrocyte diﬀ erentiation and 
enhanced OA develop ment.
Th e eﬀ ects of TGFβ on chondrocytes seem to be 
context related. Serum factors can modulate the eﬀ ect of 
TGFβ on chondrocyte proliferation. Growth of cultured 
rabbit chondrocytes decreased after TGFβ stimulation in 
the presence of a low serum concentration, while the cell 
number increased in the presence of high serum levels 
[45,46]. Th e rabbit chondrocytes demonstrated diﬀ er-
ences in TGFβ receptor expression as a function of cell 
cycle progression [47-49]. Moreover, expression of TGFβ 
receptors appeared to be changed by nitric oxide and 
ROS levels and OA chondrocytes became insensitive to 
TGFβ, which was concomitant with loss of the expression 
of TGFβ type II receptor on these chondrocytes [50,51]. 
A loss of the TGFβ type II receptor has also been 
observed by our own group during ageing and OA in 
murine models [52,53]. Moreover, proteoglycan synthesis 
is also diﬀ erentially regulated by TGFβ in rabbit and 
bovine chondrocytes depending on the diﬀ erentiation 
stage of the chondrocytes [54,55]. In calf cartilage 
explants, proteoglycan synthesis is stimulated by TGFβ in 
a dose-dependent manner [56,57]. From these obser va-
tions it can be concluded that, in general, TGFβ maintains 
chondrocyte and cartilage homeostasis but that changes 
in diﬀ erentiation stage and associated alterations in 
receptor expression modify the eﬀ ect of TGFβ on 
chondrocyte function.
We have shown in young mice that TGFβ has favorable 
eﬀ ects on cartilage, such as stimulation of proteoglycan 
synthesis in cartilage [58]. In old mice, however, stimu-
lation of aggrecan synthesis by TGFβ is reduced – and 
this is associated with a loss in ALK5 expression, and 
TGFβ type II receptor expression, on articular chondro-
cytes [59]. Livne and colleagues showed in mandibular 
chondrocytes a strong age-related decrease in stimulation 
of proteo glycan synthesis by TGFβ in young mice 
(1 month old, +120%) and old mice (18 months old, +7%) 
[59,60]. Nonchondrocytic cells have also been shown to 
display a diminished response to TGFβ during ageing. 
Smooth muscle cells derived from old rats produce 
normal levels of TGFβ but fail to respond to the 
inhibitory eﬀ ects of this growth factor in contrast to 
young cells [61]. Th e response to TGFβ appears to be age 
related and a change in TGFβ signaling can play a role in 
age-related diseases such as OA.
Control of chondrocyte diff erentiation by SMADs
Activation of the Smad1/5/8 route in chondrocytes is 
strongly associated with chondrocyte terminal diﬀ eren-
tiation and hypertrophy [62]. Bone morphogenetic protein 
itself or activation of the bone morphogenetic protein 
pathway (Smad1/5/8) leads, both in the growth plate and 
in articular chondrocytes, to expression of terminal 
diﬀ er entiation markers [63-65]. Signaling via Smad1 
cooperates with the transcription factor Runx2 (CBFA1) 
to induce chondrocyte terminal diﬀ erentiation. Th is 
cross-talk between the bone morphogenetic protein-
associated Smads and Runx2 is essential to stimulate the 
expression of hypertrophy markers in diﬀ erentiating 
chondrocytes [66]. Blocking the Smad1/5/8 route by 
overexpression of Smad6 reduced the expression of both 
type X collagen and alkaline phosphatase activity in 
chondro cytes, while using Smad6 antisense had an 
opposite eﬀ ect [67]. Moreover, in vivo inhibition of 
Smad1/5/8 phosphory lation, as observed in Smad6 
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transgenic mice, was associated with delayed chondro-
cyte hypertrophy [68]. In articular chondrocytes treated 
with azacytidine, reduced Smad2 and Smad3 expression 
and signaling and increased Smad1/5 expression 
correlated with elevated synthesis of type X collagen and 
alkaline phosphatase. Th ese observations clearly demon-
strate that terminal diﬀ erentiation of articular chondro-
cytes is associated with dominant signaling via the 
Smad1/5/8 pathway [69].
Th e latter observation shows not only that activation of 
the Smad1/5/8 route leads to terminal diﬀ erentiation but 
also that loss of Smad2/3 can lead to induction of 
chondrocyte terminal diﬀ erentiation. Th e inhibitory 
eﬀ ects of TGFβ on chondrocyte maturation is mediated 
by the Smad2/3 pathway, as has been shown by 
overexpression of dominant negative Smad2 and Smad3 
in chondrocytes. Mutant mice deﬁ cient for functional 
Smad3 show abnormally increased numbers of type X 
collagen-expressing chondrocytes in articular cartilage. 
Overexpression of both Smad2 and Smad3 blocked 
spontaneous maturation in Smad3-deﬁ cient chondro-
cytes [70,71]. Smad2 and Smad3 are key mediators of the 
inhibitory eﬀ ect of TGFβ on chondrocyte terminal diﬀ er-
entiation [72]. Without Smad2/3 signaling, chondrocytes 
break their quiescent state and undergo anomalous 
terminal diﬀ erentiation. Apparently the balance between 
Smad1/5/8 signaling and Smad2/3 signaling controls 
chondrocyte diﬀ erentiation.
Th e wnt signaling pathways are involved in chondro-
cyte diﬀ erentiation and OA development [73]. Enhanced 
and decreased wnt signaling both result in cartilage loss 
[74,75]. Furthermore, the wnt inhibitor dickkopf1 stimu-
lated chondrocyte apoptosis in OA joints [76]. Increased 
wnt signaling can have a direct eﬀ ect on chondrocyte 
diﬀ erentiation but it can also alter diﬀ erentiation by 
variable modulation of the Smad2/3 and Smad1/5/8 
pathways. wnt signaling leads to inhibition of the activity 
of the GSK3 kinase, which resulted in Xenopus embryos 
in prolonged duration of the Smad1 signal [77]. If a 
similar mechanism takes place in chondrocytes, enhanced 
wnt signaling will result in augmented terminal 
diﬀ er entiation.
Chondrocyte diﬀ erentiation is regulated by Sox9, and 
additional Sox molecules, but chondrocyte terminal 
diﬀ erentiation is rigorously controlled by the transcrip-
tion factor Runx2 [78,79]. Mice lacking Runx2 do not 
show chondrocyte terminal diﬀ erentiation, and bone 
formation via this pathway is totally blocked [80]. Smad 
pathways are integrated via Runx2 to control chondrocyte 
terminal diﬀ er entiation. Interaction of Runx2 with 
Smad1 facili tates the function of Runx2 in stimulating 
terminal diﬀ erentiation, while Smad3 blocks Runx2 
function [81-83]. Th e Smad2/3 and Smad1/5/8 balance 
controls the Runx2 function and terminal diﬀ erentiation.
Change in transforming growth factor beta 
signaling in ageing chondrocytes and osteoarthritis
We have demonstrated an age-related loss of TGFβ type I 
receptor ALK5 and phosphorylation of Smad2/3 in 
murine articular cartilage [84]. Expression of non phos-
phorylated Smad2 was not altered during ageing. 
Moreover, in two experimental models of OA – the 
DMM (meniscus destabilization) model and STR/ORT 
mice (spontaneous OA) – development of the disease 
was correlated with a loss of ALK5 expression. Expression 
of the alternative TGFβ receptor, ALK1, did not decrease 
to a similar extent as ALK5 [85]. As a result, the ratio of 
ALK1/ALK5 expressing cells strongly increased in OA 
articular chondrocytes. During ageing of C57Bl mice, the 
ratio ALK1/ALK5 increased up to sixfold. In the DMM 
model, OA develops on the medial tibial side while the 
lateral side is relatively protected. A more than threefold 
increase in the ALK1/ALK5 ratio was observed on the 
medial side while the ratio on the lateral side was 
unaﬀ ected. STR/ORT mice develop OA starting at the 
medial tibia from an age of 2 to 3 months. Th e ALK1/
ALK5 ratio was 5 on the medial tibia at an age of 3 
months and was 18 in 1-year-old animals. Th e lateral 
tibia showed a ratio increase from 1 to 5 in the same 
period. Clearly an increased ALK1/ALK5 ratio in 
chondrocytes is associated with ageing and OA 
development [85].
We postulate that the loss of ALK5 expression and the 
concomitant elevated ratio of ALK1/ALK5 will have 
profound eﬀ ects on chondrocyte behavior. Th e eﬀ ect of 
TGFβ on chondrocytes will be governed by the ALK1/
ALK5 ratio. A prevailing expression of ALK5 will result 
in a dominance of the Smad2/3 signaling route, while 
ALK1 dominance will result in a stronger Smad1/5/8 
pathway. Th e balance of these routes has been shown to 
control chondrocyte diﬀ erentiation (see above).
We and others have shown that TGFβ signals in 
chondro cytes not only via ALK5 but also via ALK1 [86]. 
Exposure of chondrocytes to TGFβ results in both 
Smad2/3 and Smad1/5/8 phosphorylation within 15 to 30 
minutes [85]. In addition, overexpression of constitutive 
active ALK5 (Smad2/3) results in increased expression of 
aggrecan while constitutive ALK1 (Smad1/5/8) expres-
sion leads to elevated expression of MMP-13. Blocking 
ALK5 expression using siRNA resulted in elevated 
expression of MMP-13 [85]. Th e ALK1 (Smad1/5/8) and 
ALK5 (Smad3) signaling balance in chondrocytes 
apparently determines MMP-13 expression. In addition, 
a clear trend towards elevated type II collagen and 
aggrecan expression was observed in cells with constitu-
tive active ALK1. Noticeably, human osteoarthritic 
cartilage demonstrated a signiﬁ cant correlation between 
ALK1 and MMP-13 mRNA expression and a trend 
(P  =  0.05 to 0.1) with type II collagen and aggrecan 
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expression. Th ese observations indicate that ALK1 signal-
ing can induce a chondrocyte phenotype similar to that 
found in OA cartilage, a phenotype with simultaneous 
enhanced expression of matrix molecules and MMP-13.
We hypothesize that articular chondrocytes reside in a 
quiescent state in young healthy cartilage due to the 
inhibitory eﬀ ect of TGFβ, via Smad2/3, on the progres-
sion of chondrocyte diﬀ erentiation. During ageing of 
chondro cytes and OA development, signaling through 
ALK1 and Smad1/5/8 is increased in favor of signaling 
via ALK5 and Smad2/3. Th e dominant Smad1/5/8 
signaling triggers the articular chondrocytes to leave their 
quies cent state (Figure  1). Th is leads to a chondrocyte 
phenotype with characteristics analogous to terminal 
diﬀ erentiated growth plate chondrocytes – a chondrocyte 
with an autolytic phenotype typiﬁ ed by degradation of its 
surrounding cartilage matrix, as can be found in OA 
cartilage.
Th is hypothesis can explain the often enigmatic eﬀ ects 
of TGFβ on articular cartilage. Th e eﬀ ect of TGFβ on 
chondrocytes will be determined by the relative expres-
sion of ALK5 and ALK1. In general, we have observed in 
young animals that TGFβ is protective for articular 
cartilage [84,87-90]. Prolonged exposure of cartilage to 
high TGFβ levels, however, induces osteoarthritic lesions 
in murine knee joints, starting in the deep zones [91]. We 
have observed that the chondrocytes in the deep zone, 
just above the tidemark, show high ALK1 expression 
(personal observation). In old animals, showing a 
decrease in the ALK5/ALK1 ratio, the protective eﬀ ect of 
TGFβ is lost and TGFβ can act as an OA-inducing factor 
[85,92,93] (Table 1).
In conclusion, loss of the Smad2/3 signaling and 
relatively enhanced Smad1/5/8 signaling can explain the 
enigmatic observation in OA cartilage of elevated 
expression of both matrix molecules and proteolytic 
enzymes, like MMP-13. Moreover, the age-related loss of 
ALK5 signaling in chondrocytes can give a clue to the 
high correlation between ageing and OA development. 
Interestingly, a remarkable relationship has been reported 
between reduced TGFβ signaling and another, highly age-
related aﬄ  iction, Alzheimer’s disease [94,95]. Alzheimer’s 
disease is characterized by progressive neurodegeneration 
and cerebral accumulation of the β-amyloid peptide. 
Reduced TGFβ type II receptor expres sion and signaling 
has been demonstrated in Alzheimer’s disease. Over-
expression of dominant negative Smad3 causes neuro-
degeneration in cell cultures, indicat ing that loss of 
Figure 1. Alterations in transforming growth factor beta signaling cause changes in chondrocyte diff erentiation and osteoarthritis 
development. Transforming growth factor beta (TGFβ) can either signal by the Smad2/3 route (canonical) or the Smad1/5/8 route. Smad2/3 and 
Smad1/5/8 form a complex with Smad4 that enters the nucleus and modulates gene expression and Runx2 function. The signaling by Smad2/3 
and Smad1/5/8 is diff erentially modifi ed by a number of intracellular molecules. Both Smad routes are blocked by Smad7, while Smad6 blocks 
preferentially the Smad1/5/8 pathway [100,101]. wnt signaling modifi es these pathways by stabilization of Smad1/5/8 [102]. Smurf1 and Smurf2 
are E3 ubiquitin ligases that inhibit Smad signaling. Smurf1 triggers the degradation of Smad1/5/8 while Smurf2 stimulates mainly the degradation 
of Smad2/3 [103]. Mitogen-activated protein kinases (MAPKs) modulate the stability and degradation of the Smads by phosphorylation of these 
molecules [102].
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Smad2/3 signaling is involved. Reducing neuronal TGFβ 
signaling via the Smad2/3 pathway in mice resulted in age-
dependent neurodegeneration. Th ese ﬁ ndings show that 
reduced TGFβ Smad3-dependent signaling in neuronal 
cells increases age-dependent neuro degeneration and 
Alzheimer’s disease-like symp toms. Th is observation 
points to a striking similarity between authentic Alzheimer’s 
disease and Alzheimer’s disease of the joint – OA.
Targets for therapy
We postulate that the OA process is driven by the loss of 
the Smad2/3 block on diﬀ erentiation in articular 
chondrocytes, leading to progression of chondrocyte 
diﬀ erentiation and an autolytic phenotype. In the early 
stages of OA – bearing in mind that OA is initially a focal 
process – not all chondrocytes will be at the same stage 
of diﬀ erentiation. A mixture of cell populations will be 
present in OA cartilage. Some chondrocytes will have 
progressed in their diﬀ erentiation to an OA chondrocyte 
phenotype, triggered by a loss of the Smad2/3 block. 
Other cells will still be in a quiescent, healthy state of 
diﬀ erentiation. Th e latter cells can be targets for therapy 
to block further progression of the OA process. Blocking 
the progression of chondrocyte diﬀ erentiation will block 
further expansion of the OA process in remaining healthy 
cartilage.
Loss of Smad2/3 signaling is at the root of the OA 
process in our view. To inhibit articular chondrocytes in 
their deviant diﬀ erentiation, this pathway has to be 
stimulated at the same time as circumventing the role of 
the ALK1 receptor. Compounds speciﬁ cally stimulating 
the Smad2/3 route should be developed. A similar 
strategy, using TGFβ mimetics, has been proposed to 
treat Alzheimer’s disease [96]. TGFβ mimetics have 
already been developed that can mimic TGFβ eﬀ ects on 
cells [97].
An alternative therapy could be stimulation of one of 
the other Smad2/3 routes in chondrocytes. Signaling via 
the activin ALK4 and ALK7 receptors leads to activation 
of the Smad2/3 pathway [98]. Little is known about the 
expression of these receptors in old chondrocytes, but 
potentially these receptors could be targets to enhance 
Smad2/3 signaling in chondrocytes in OA.
An alternative strategy would be blocking ALK1 or the 
Smad1/5/8 pathway in chondrocytes to block the trigger 
that stimulates progression of chondrocyte diﬀ erentia-
tion. Since ALK1 is involved in vessel formation, blocking 
ALK1 can interfere with this process [99]. As blockers of 
ALK1 to treat OA will be mainly applied in middle-aged 
and older people, additional eﬀ ects of this treatment are 
expected to be limited. General blocking of the 
Smad1/5/8 pathway using kinase blockers that inhibit the 
activity of ALK1, ALK2, ALK3 and ALK6 is an alternative 
option to stop chondro cyte aberrant diﬀ erentiation.
Th e potential side eﬀ ects of the above therapies are 
unclear. Eﬀ ects on growth plate chondrocytes will be absent 
since the growth plates are not present in elderly humans. 
Th e eﬀ ects of stimulating the Smad2/3 pathway using TGFβ 
mimetics or the ALK4/7 pathway could result in side eﬀ ects, 
such as induction of ﬁ brosis. Block ing ALK1 will have few 
side eﬀ ects due to the restricted eﬀ ect of ALK1 in vessel 
formation, which is anticipated to be relatively unimportant 
in elderly people. Th e eﬀ ects of general inhibition of the 
Smad1/5/8 pathway in elderly people are hard to predict but 
this might interfere with bone metabolism. Bone 
morphogenetic protein signaling is known to be involved in 
both bone formation and bone degradation, the latter by 
stimulation of osteoclast maturation.
Table 1. Arguments implying a role for alterations in TGFβ signaling in osteoarthritis development
Genetic studies point to a role for TGFβ in osteoarthritis
Mice that express a dominant negative TGFβ type II receptor in skeletal tissues showed enhanced chondrocyte hypertrophy and osteoarthritis
Mice defi cient for Smad3 or latent TGFβ binding protein 3 demonstrated enhanced chondrocyte hypertrophy and osteoarthritis
Cartilage protective eff ects of TGFβ are lost in ageing mice
ALK1/ALK5 expression ratio is increased in cartilage in ageing mice and experimental osteoarthritis
ALK1 overexpression results in MMP-13 upregulation in chondrocytes
Blocking ALK5 expression, using siRNA, leads to elevated expression of MMP-13
In human osteoarthritis cartilage, ALK1 expression and MMP-13 expression signifi cantly correlate
Smad2/3 signaling inhibits, while Smad1/5/8 signaling stimulates, progression of chondrocyte diff erentiation 
In osteoarthritis, synthesis of matrix molecules (type II collagen) is increased – indicating no dominant role for catabolic cytokines
Alterations in TGFβ signaling in osteoarthritis can provide an explanation for the enigmatic observation of concomitant increased synthesis of matrix molecules 
(type II collagen) and increased MMP-13 production
MMP-13, matrix metalloproteinase 13; TGFβ, transforming growth factor beta.
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Conclusion
Until now no eﬀ ective therapy has been developed for 
OA that interferes with disease progression. Painkilling 
and joint replacement are the only options at this 
moment. Th e proposed treatment attacks the OA process 
at its core, blocking the generation of chondrocytes with 
an autolytic phenotype. Th e proposed OA mechanism 
and potential therapies open the venue to new strategies 
to treat this common crippling joint disease.
Abbreviations
IL = interleukin; MMP-13 = matrix metalloproteinase 13; OA = osteoarthritis; 
TGFβ = transforming growth factor beta; TNF = tumor necrosis factor.
Competing interests
The authors declare that they have no competing interests.
Published: 29 January 2010
References
1. Pullig O, Weseloh G, Ronneberger D, Kakonen S, Swoboda B: Chondrocyte 
diff erentiation in human osteoarthritis: expression of osteocalcin in 
normal and osteoarthritic cartilage and bone. Calcif Tissue Int 2000, 
67:230-240.
2. Kirsch T, Swoboda B, Nah H: Activation of annexin II and V expression, 
terminal diff erentiation, mineralization and apoptosis in human 
osteoarthritic cartilage. Osteoarthritis Cartilage 2000, 8:294-302.
3. Aigner T, Reichenberger E, Bertling W, Kirsch T, Stoss H, von der MK: Type X 
collagen expression in osteoarthritic and rheumatoid articular cartilage. 
Virchows Arch B Cell Pathol Incl Mol Pathol 1993, 63:205-211.
4. Li T, Xiao J, Wu Z, Qiu G: Over-expression of c-maf by chondrocytes in 
osteoarthritis. J Int Med Res 2009, 37:129-135.
5. Wang X, Manner PA, Horner A, Shum L, Tuan RS, Nuckolls GH: Regulation of 
MMP-13 expression by RUNX2 and FGF2 in osteoarthritic cartilage. 
Osteoarthritis Cartilage 2004, 12:963-973.
6. Reboul P, Pelletier JP, Tardif G, Cloutier JM, Martel-Pelletier J: The new 
collagenase, collagenase-3, is expressed and synthesized by human 
chondrocytes but not by synoviocytes. A role in osteoarthritis. J Clin Invest 
1996, 97:2011-2019.
7. Inada M, Wang Y, Byrne MH, Rahman MU, Miyaura C, Lopez-Otin C, Krane SM: 
Critical roles for collagenase-3 (Mmp13) in development of growth plate 
cartilage and in endochondral ossifi cation. Proc Natl Acad Sci U S A 2004, 
101:17192-17197.
8. Stickens D, Behonick DJ, Ortega N, Heyer B, Hartenstein B, Yu Y, Fosang AJ, 
Schorpp-Kistner M, Angel P, Werb Z: Altered endochondral bone 
development in matrix metalloproteinase 13-defi cient mice. Development 
2004, 131:5883-5895.
9. Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, 
Poole AR, Veale DJ: Turnover of type II collagen and aggrecan in cartilage 
matrix at the onset of infl ammatory arthritis in humans: relationship to 
mediators of systemic and local infl ammation. Arthritis Rheum 2003, 
48:3085-3095.
10. Poole AR, Rizkalla G, Ionescu M, Reiner A, Brooks E, Rorabeck C, Bourne R, 
Bogoch E: Osteoarthritis in the human knee: a dynamic process of 
cartilage matrix degradation, synthesis and reorganization. Agents Actions 
Suppl 1993, 39:3-13.
11. Hermansson M, Sawaji Y, Bolton M, Alexander S, Wallace A, Begum S, Wait R, 
Saklatvala J: Proteomic analysis of articular cartilage shows increased type 
II collagen synthesis in osteoarthritis and expression of inhibin betaA 
(activin A), a regulatory molecule for chondrocytes. J Biol Chem 2004, 
279:43514-43521.
12. Aigner T, Zien A, Gehrsitz A, Gebhard PM, McKenna L: Anabolic and catabolic 
gene expression pattern analysis in normal versus osteoarthritic cartilage 
using complementary DNA-array technology. Arthritis Rheum 2001, 
44:2777-2789.
13. Martel-Pelletier J, McCollum R, DiBattista J, Faure MP, Chin JA, Fournier S, 
Sarfati M, Pelletier JP: The interleukin-1 receptor in normal and 
osteoarthritic human articular chondrocytes. Identifi cation as the type I 
receptor and analysis of binding kinetics and biologic function. Arthritis 
Rheum 1992, 35:530-540.
14. Shlopov BV, Gumanovskaya ML, Hasty KA: Autocrine regulation of 
collagenase 3 (matrix metalloproteinase 13) during osteoarthritis. Arthritis 
Rheum 2000, 43:195-205.
15. Dingle JT: Catabolin – a cartilage catabolic factor from synovium. Clin 
Orthop Relat Res 1981, 156:219-231.
16. Martel-Pelletier J: Pathophysiology of osteoarthritis. Osteoarthritis Cartilage 
2004, 12(Suppl A):S31-S33.
17. Vuolteenaho K, Moilanen T, Jalonen U, Lahti A, Nieminen R, van Beuningen 
HM, van der Kraan PM, Moilanen E. TGFβ inhibits IL-1-induced iNOS 
expression and NO production in immortalized chondrocytes. Infl amm Res 
2005, 54:420-427.
18. Pasternak RD, Hubbs SJ, Caccese RG, Marks RL, Conaty JM, DiPasquale G: 
Interleukin-1 stimulates the secretion of proteoglycan- and collagen-
degrading proteases by rabbit articular chondrocytes. Clin Immunol 
Immunopathol 1986, 41:351-367.
19. Takahashi N, Rieneck K, van der Kraan PM, van Beuningen HM, Vitters EL, 
Bendtzen K, van den Berg WB: Elucidation of IL-1/TGF-β interactions in 
mouse chondrocyte cell line by genome-wide gene expression. 
Osteoarthritis Cartilage 2005, 13:426-438.
20. Bocquet J, Daireaux M, Langris M, Jouis V, Pujol JP, Beliard R, Loyau G: Eff ect of 
a interleukin-1 like factor (mononuclear cell factor) on proteoglycan 
synthesis in cultured human articular chondrocytes. Biochem Biophys Res 
Commun 1986, 134:539-549.
21. Goldring MB, Birkhead JR, Suen LF, Yamin R, Mizuno S, Glowacki J, Arbiser JL, 
Apperley JF. Interleukin-1 beta-modulated gene expression in 
immortalized human chondrocytes. J Clin Invest 1994, 94:2307-2316.
22. Bhatnagar R, Penfornis H, Mauviel A, Loyau G, Saklatvala J, Pujol JP: 
Interleukin-1 inhibits the synthesis of collagen by fi broblasts. Biochem Int 
1986, 13:709-720.
23. Redini F, Galera P, Mauviel A, Loyau G, Pujol JP: Transforming growth factor 
beta stimulates collagen and glycosaminoglycan biosynthesis in cultured 
rabbit articular chondrocytes. FEBS Lett 1988, 234:172-176.
24. Redini F, Daireaux M, Mauviel A, Galera P, Loyau G, Pujol JP: Characterization 
of proteoglycans synthesized by rabbit articular chondrocytes in response 
to transforming growth factor-beta (TGF-β). Biochim Biophys Acta 1991, 
1093:196-206.
25. Goldring MB: The role of cytokines as infl ammatory mediators in 
osteoarthritis: lessons from animal models. Connect Tissue Res 1999, 40:1-11.
26. van der Kraan PM, Glansbeek HL, Vitters EL, van den Berg WB: Early elevation 
of transforming growth factor-beta, decorin, and biglycan mRNA levels 
during cartilage matrix restoration after mild proteoglycan depletion. 
J Rheumatol 1997, 24:543-549.
27. Govinden R, Bhoola KD: Genealogy, expression, and cellular function of 
transforming growth factor-beta. Pharmacol Ther 2003, 98:257-265.
28. Lawrence DA: Latent-TGF-β: an overview. Mol Cell Biochem 2001, 
219:163-170.
29. Konig HG, Kogel D, Rami A, Prehn JH: TGFβ1 activates two distinct type I 
receptors in neurons: implications for neuronal NF-κB signaling. J Cell Biol 
2005, 168:1077-1086.
30. Finnson KW, Parker WL, ten DP, Thorikay M, Philip A: ALK1 opposes ALK5/
Smad3 signaling and expression of extracellular matrix components in 
human chondrocytes. J Bone Miner Res 2008, 23:896-906.
31. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, 
Karlsson S, ten Dijke P: Activin receptor-like kinase (ALK)1 is an antagonistic 
mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 2003, 12:817-828.
32. Wu X, Ma J, Han JD, Wang N, Chen YG: Distinct regulation of gene 
expression in human endothelial cells by TGF-β and its receptors. 
Microvasc Res 2006, 71:12-19.
33. Seki T, Hong KH, Oh SP: Nonoverlapping expression patterns of ALK1 and 
ALK5 reveal distinct roles of each receptor in vascular development. Lab 
Invest 2006, 86:116-129.
34. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P: 
Balancing the activation state of the endothelium via two distinct 
TGF-beta type I receptors. EMBO J 2002, 21:1743-1753.
35. Zhang YE: Non-Smad pathways in TGF-βsignaling. Cell Res 2009, 19:128-139.
36. Sorrentino A, Thakur N, Grimsby S, Marcusson A, von B, V, Schuster N, Zhang 
S, Heldin CH, Landstrom M: The type I TGF-βreceptor engages TRAF6 to 
activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 2008, 
10:1199-1207.
van der Kraan et al. Arthritis Research & Therapy 2010, 12:201 
http://arthritis-research.com/content/12/1/201
Page 7 of 9
37. Kamiya M, Harada A, Mizuno M, Iwata H, Yamada Y: Association between a 
polymorphism of the transforming growth factor-β1 gene and genetic 
susceptibility to ossifi cation of the posterior longitudinal ligament in 
Japanese patients. Spine 2001, 26:1264-1266.
38. Yamada Y, Okuizumi H, Miyauchi A, Takagi Y, Ikeda K, Harada A: Association of 
transforming growth factor beta 1 genotype with spinal osteophytosis in 
Japanese women. Arthritis Rheum 2000, 43:452-460.
39. Kizawa H, Kou I, Iida A, Sudo A, Miyamoto Y, Fukuda A, Mabuchi A, Kotani A, 
Kawakami A, Yamamoto S, Uchida A, Nakamura K, Notoya K, Nakamura Y, 
Ikegawa S: An aspartic acid repeat polymorphism in asporin inhibits 
chondrogenesis and increases susceptibility to osteoarthritis. Nat Genet 
2005, 37:138-144.
40. Rodriguez-Lopez J, Pombo-Suarez M, Liz M, Gomez-Reino JJ, Gonzalez A: 
Lack of association of a variable number of aspartic acid residues in the 
asporin gene with osteoarthritis susceptibility: case–control studies in 
Spanish Caucasians. Arthritis Res Ther 2006, 8:R55.
41. Jiang Q, Shi D, Yi L, Ikegawa S, Wang Y, Nakamura T, Qiao D, Liu C, Dai J: 
Replication of the association of the aspartic acid repeat polymorphism in 
the asporin gene with knee-osteoarthritis susceptibility in Han Chinese. 
J Hum Genet 2006, 51:1068-1072.
42. Serra R, Johnson M, Filvaroff  EH, Laborde J, Sheehan DM, Derynck R, Moses 
HL: Expression of a truncated, kinase defective TGF-beta type II receptor in 
mouse skeletal tissue promotes terminal chondrocyte diff erentiation and 
osteoarthritis. J Cell Biol 1997, 139:541-552.
43. Yang X, Chen L, Xu XL, Li CL, Huang CF, Deng CX: TGF-β/Smad3 signals 
repress chondrocyte hypertrophic diff erentiation and are required for 
maintaining articular cartilage. J Cell Biol 2001, 153:35-46.
44. Dabovic B, Chen Y, Colarossi C, Zambuto L, Obata H, Rifkin DB: Bone defects 
in latent TGF-β binding protein (Ltbp)-3 null mice, a role for Ltbp in TGF-
βpresentation. J Endocrinol 2002, 175:129-141.
45. Vivien D, Galera P, Loyau G, Pujol JP: Diff erential response of cultured rabbit 
articular chondrocytes (RAC) to transforming growth factor beta (TGF-β) 
– evidence for a role of serum factors. Eur J Cell Biol 1991, 54:217-223.
46. Vivien D, Galera P, Lebrun E, Daireaux M, Loyau G, Pujol JP: TGF-β-induced 
G2/M delay in proliferating rabbit articular chondrocytes is associated 
with an enhancement of replication rate and a cAMP decrease: possible 
involvement of pertussis toxin-sensitive pathway. J Cell Physiol 1992, 
150:291-298.
47. Vivien D, Redini F, Galera P, Lebrun E, Loyau G, Pujol JP: Rabbit articular 
chondrocytes (RAC) express distinct transforming growth factor-beta 
receptor phenotypes as a function of cell cycle phases. Exp Cell Res 1993, 
205:165-170.
48. Pujol JP, Galera P, Pronost S, Boumediene K, Vivien D, Macro M, Min W, Redini 
F, Penfornis H, Daireaux M: Transforming growth factor-beta (TGF-β) and 
articular chondrocytes. Ann Endocrinol (Paris) 1994, 55:109-120.
49. Boumediene K, Felisaz N, Pujol JP: Cell-cycle-dependent expression of 
transforming growth factor beta type I receptor correlates with 
diff erential proliferative eff ects of TGFβ1 in articular chondrocytes. Exp Cell 
Res 1998, 243:173-184.
50. Pujol JP, Chadjichristos C, Legendre F, Bauge C, Beauchef G, 
Andriamanalijaona R, Galera P, Boumediene K: Interleukin-1 and 
transforming growth factor-beta 1 as crucial factors in osteoarthritic 
cartilage metabolism. Connect Tissue Res 2008, 49:293-297.
51. Legendre F, Dudhia J, Pujol JP, Bogdanowicz P: JAK/STAT but not ERK1/ERK2 
pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of type 
II collagen, aggrecan core, and link protein transcription in articular 
chondrocytes. Association with a down-regulation of SOX9 expression. 
J Biol Chem 2003, 278:2903-2912.
52. Blaney Davidson EN, Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg 
WB: Reduced transforming growth factor-beta signaling in cartilage of old 
mice: role in impaired repair capacity. Arthritis Res Ther 2005, 7:R1338-R1347.
53. Scharstuhl A, van Beuningen HM, Vitters EL, van der Kraan PM, van den Berg 
WB: Loss of transforming growth factor counteraction on interleukin 1 
mediated eff ects in cartilage of old mice. Ann Rheum Dis 2002, 
61:1095-1098.
54. Galera P, Redini F, Vivien D, Bonaventure J, Penfornis H, Loyau G, Pujol JP: 
Eff ect of transforming growth factor-beta 1 (TGF-β 1) on matrix synthesis 
by monolayer cultures of rabbit articular chondrocytes during the 
dediff erentiation process. Exp Cell Res 1992, 200:379-392.
55. van der Kraan PM, Vitters E, van den BW: Diff erential eff ect of transforming 
growth factor beta on freshly isolated and cultured articular 
chondrocytes. J Rheumatol 1992, 19:140-145.
56. Morales TI: Transforming growth factor-beta 1 stimulates synthesis of 
proteoglycan aggregates in calf articular cartilage organ cultures. Arch 
Biochem Biophys 1991, 286:99-106.
57. Morales TI, Roberts AB: Transforming growth factor beta regulates the 
metabolism of proteoglycans in bovine cartilage organ cultures. J Biol 
Chem 1988, 263:12828-12831.
58. van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB: 
Transforming growth factor-beta 1 stimulates articular chondrocyte 
proteoglycan synthesis and induces osteophyte formation in the murine 
knee joint. Lab Invest 1994, 71:279-290.
59. Blaney Davidson EN, Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg 
WB: Reduced transforming growth factor-beta signaling in cartilage of old 
mice: role in impaired repair capacity. Arthritis Res Ther 2005, 7:R1338-R1347.
60. Livne E, Laufer D, Blumenfeld I: Diff erential response of articular cartilage 
from young growing and mature old mice to IL-1 and TGF-β. Arch Gerontol 
Geriatr 1997, 24:211-221.
61. McCaff rey TA, Falcone DJ: Evidence for an age-related dysfunction in the 
antiproliferative response to transforming growth factor-beta in vascular 
smooth muscle cells. Mol Biol Cell 1993, 4:315-322.
62. Mailhot G, Yang M, Mason-Savas A, Mackay CA, Leav I, Odgren PR: BMP-5 
expression increases during chondrocyte diff erentiation in vivo and in 
vitro and promotes proliferation and cartilage matrix synthesis in primary 
chondrocyte cultures. J Cell Physiol 2008, 214:56-64.
63. Li X, Schwarz EM, Zuscik MJ, Rosier RN, Ionescu AM, Puzas JE, Drissi H, Sheu TJ, 
O’keefe RJ: Retinoic acid stimulates chondrocyte diff erentiation and 
enhances bone morphogenetic protein eff ects through induction of 
Smad1 and Smad5. Endocrinology 2003, 144:2514-2523.
64. Nishihara A, Fujii M, Sampath TK, Miyazono K, Reddi AH: Bone 
morphogenetic protein signaling in articular chondrocyte diff erentiation. 
Biochem Biophys Res Commun 2003, 301:617-622.
65. Bau B, Haag J, Schmid E, Kaiser M, Gebhard PM, Aigner T: Bone 
morphogenetic protein-mediating receptor-associated Smads as well as 
common Smad are expressed in human articular chondrocytes but not 
up-regulated or down-regulated in osteoarthritic cartilage. J Bone Miner 
Res 2002, 17:2141-2150.
66. Drissi MH, Li X, Sheu TJ, Zuscik MJ, Schwarz EM, Puzas JE, Rosier RN, O’keefe 
RJ: Runx2/Cbfa1 stimulation by retinoic acid is potentiated by BMP2 
signaling through interaction with Smad1 on the collagen X promoter in 
chondrocytes. J Cell Biochem 2003, 90:1287-1298.
67. Li X, Ionescu AM, Schwarz EM, Zhang X, Drissi H, Puzas JE, Rosier RN, Zuscik 
MJ, O’keefe RJ: Smad6 is induced by BMP-2 and modulates chondrocyte 
diff erentiation. J Orthop Res 2003, 21:908-913.
68. Horiki M, Imamura T, Okamoto M, Hayashi M, Murai J, Myoui A, Ochi T, 
Miyazono K, Yoshikawa H, Tsumaki N: Smad6/Smurf1 overexpression in 
cartilage delays chondrocyte hypertrophy and causes dwarfi sm with 
osteopenia. J Cell Biol 2004, 165:433-445.
69. Zuscik MJ, Baden JF, Wu Q, Sheu TJ, Schwarz EM, Drissi H, O’keefe RJ, Puzas JE, 
Rosier RN: 5-Azacytidine alters TGF-βand BMP signaling and induces 
maturation in articular chondrocytes. J Cell Biochem 2004, 92:316-331.
70. Li TF, Darowish M, Zuscik MJ, Chen D, Schwarz EM, Rosier RN, Drissi H, O’Keefe 
RJ: Smad3-defi cient chondrocytes have enhanced BMP signaling and 
accelerated diff erentiation. J Bone Miner Res 2006, 21:4-16.
71. Yang X, Chen L, Xu X, Li C, Huang C, Deng CX: TGF-β/Smad3 signals repress 
chondrocyte hypertrophic diff erentiation and are required for 
maintaining articular cartilage. J Cell Biol 2001, 153:35-46.
72. Ferguson CM, Schwarz EM, Reynolds PR, Puzas JE, Rosier RN, O’keefe RJ: 
Smad2 and 3 mediate transforming growth factor-beta1-induced 
inhibition of chondrocyte maturation. Endocrinology 2000, 141:4728-4735.
73. Zhou S, Eid K, Glowacki J: Cooperation between TGF-β and Wnt pathways 
during chondrocyte and adipocyte diff erentiation of human marrow 
stromal cells. J Bone Miner Res 2004, 19:463-470.
74. Zhu M, Tang D, Wu Q, Hao S, Chen M, Xie C, Rosier RN, O’Keefe RJ, Zuscik M, 
Chen D: Activation of β-catenin signaling in articular chondrocytes leads 
to osteoarthritis-like phenotype in adult beta-catenin conditional 
activation mice. J Bone Miner Res 2009, 24:12-21.
75. Zhu M, Chen M, Zuscik M, Wu Q, Wang YJ, Rosier RN, O’Keefe RJ, Chen D: 
Inhibition of β-catenin signaling in articular chondrocytes results in 
articular cartilage destruction. Arthritis Rheum 2008, 58:2053-2064.
76. Weng LH, Wang CJ, Ko JY, Sun YC, Su YS, Wang FS: Infl ammation induction of 
Dickkopf-1 mediates chondrocyte apoptosis in osteoarthritic joint. 
van der Kraan et al. Arthritis Research & Therapy 2010, 12:201 
http://arthritis-research.com/content/12/1/201
Page 8 of 9
Osteoarthritis Cartilage 2009, 17:919-929.
77. Fuentealba LC, Eivers E, Ikeda A, Hurtado C, Kuroda H, Pera EM, De Robertis 
EM: Integrating patterning signals: Wnt/GSK3 regulates the duration of 
the BMP/Smad1 signal. Cell 2007, 131:980-993.
78. Furumatsu T, Ozaki T, Asahara H: Smad3 activates the Sox9-dependent 
transcription on chromatin. Int J Biochem Cell Biol 2009, 41:1198-1204.
79. Mackay AM, Beck SC, Murphy JM, Barry FP, Chichester CO, Pittenger MF: 
Chondrogenic diff erentiation of cultured human mesenchymal stem cells 
from marrow. Tissue Eng 1998, 4:415-428.
80. Hecht J, Seitz V, Urban M, Wagner F, Robinson PN, Stiege A, Dieterich C, 
Kornak U, Wilkening U, Brieske N, Zwingman C, Kidess A, Stricker S, Mundlos 
S: Detection of novel skeletogenesis target genes by comprehensive 
analysis of a Runx2–/– mouse model. Gene Expr Patterns 2007, 7:102-112.
81. Javed A, Bae JS, Afzal F, Gutierrez S, Pratap J, Zaidi SK, Lou Y, van Wijnen AJ, 
Stein JL, Stein GS, Lian JB: Structural coupling of Smad and Runx2 for 
execution of the BMP2 osteogenic signal. J Biol Chem 2008, 283:8412-8422.
82. Leboy P, Grasso-Knight G, D’Angelo M, Volk SW, Lian JV, Drissi H, Stein GS, 
Adams SL: Smad–Runx interactions during chondrocyte maturation. J Bone 
Joint Surg Am 2001, 83A(Suppl 1):S15-S22.
83. Hjelmeland AB, Schilling SH, Guo X, Quarles D, Wang XF: Loss of Smad3-
mediated negative regulation of Runx2 activity leads to an alteration in 
cell fate determination. Mol Cell Biol 2005, 25:9460-9468.
84. Blaney Davidson EN, Vitters EL, van der Kraan PM, van den Berg WB. 
Expression of transforming growth factor-beta (TGFβ) and the TGFβ 
signalling molecule SMAD-2P in spontaneous and instability-induced 
osteoarthritis: role in cartilage degradation, chondrogenesis and 
osteophyte formation. Ann Rheum Dis 2006, 65:1414-1421.
85. Blaney Davidson EN, Remst DF, Vitters EL, van Beuningen HM, Blom AB, 
Goumans MJ, van den Berg WB, van der Kraan PM: Increase in ALK1/ALK5 
ratio as a cause for elevated MMP-13 expression in osteoarthritis in 
humans and mice. J Immunol 2009, 182:7937-7945.
86. Finnson KW, Parker WL, ten DP, Thorikay M, Philip A: ALK1 opposes ALK5/
Smad3 signaling and expression of extracellular matrix components in 
human chondrocytes. J Bone Miner Res 2008, 23:896-906.
87. van Beuningen HM, Glansbeek HL, van der Kraan PM, van den Berg WB: 
Diff erential eff ects of local application of BMP-2 or TGF-β 1 on both 
articular cartilage composition and osteophyte formation. Osteoarthritis 
Cartilage 1998, 6:306-317.
88. Glansbeek HL, van Beuningen HM, Vitters EL, van der Kraan PM, van den Berg 
WB: Stimulation of articular cartilage repair in established arthritis by local 
administration of transforming growth factor-beta into murine knee 
joints. Lab Invest 1998, 78:133-142.
89. van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB: In vivo 
protection against interleukin-1-induced articular cartilage damage by 
transforming growth factor-beta 1: age-related diff erences. Ann Rheum Dis 
1994, 53:593-600.
90. van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB: Protection 
from interleukin 1 induced destruction of articular cartilage by 
transforming growth factor beta: studies in anatomically intact cartilage 
in vitro and in vivo. Ann Rheum Dis 1993, 52:185-191.
91. van Beuningen HM, Glansbeek HL, van der Kraan PM, van den Berg WB: 
Osteoarthritis-like changes in the murine knee joint resulting from intra-
articular transforming growth factor-beta injections. Osteoarthritis Cartilage 
2000, 8:25-33.
92. Scharstuhl A, van Beuningen HM, Vitters EL, van der Kraan PM, van den Berg 
WB: Loss of transforming growth factor counteraction on interleukin 1 
mediated eff ects in cartilage of old mice. Ann Rheum Dis 2002, 
61:1095-1098.
93. Blaney Davidson EN, Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg 
WB: Reduced transforming growth factor-beta signaling in cartilage of old 
mice: role in impaired repair capacity. Arthritis Res Ther 2005, 7:R1338-R1347.
94. Tesseur I, Zou K, Esposito L, Bard F, Berber E, Can JV, Lin AH, Crews L, Tremblay 
P, Mathews P, Mucke L, Masliah E, Wyss-Coray T: Defi ciency in neuronal 
TGF-β signaling promotes neurodegeneration and Alzheimer’s pathology. 
J Clin Invest 2006, 116:3060-3069.
95. Das P, Golde T: Dysfunction of TGF-β signaling in Alzheimer’s disease. J Clin 
Invest 2006, 116:2855-2857.
96. Zhang H, Zou K, Tesseur I, Wyss-Coray T: Small molecule TGF-β mimetics as 
potential neuroprotective factors. Curr Alzheimer Res 2005, 2:183-186.
97. Glaser KB, Li J, Aakre ME, Morgan DW, Sheppard G, Stewart KD, Pollock J, Lee 
P, O’Connor CZ, Anderson SN, Mussatto DJ, Wegner CW, Moses HL: 
Transforming growth factor beta mimetics: discovery of 
7-[4-(4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a biaryl 
hydroxamate inhibitor of histone deacetylase. Mol Cancer Ther 2002, 
1:759-768.
98. Bernard DJ, Lee KB, Santos MM: Activin B can signal through both ALK4 and 
ALK7 in gonadotrope cells. Reprod Biol Endocrinol 2006, 13:52.
99. Fernandez L, Sanz-Rodriguez F, Blanco FJ, Bernabeu C, Botella LM: Hereditary 
hemorrhagic telangiectasia, a vascular dysplasia aff ecting the TGF-β 
signaling pathway. Clin Med Res 2006, 4:66-78.
100. Li X, Ionescu AM, Schwarz EM, Zhang X, Drissi H, Puzas JE, Rosier RN, Zuscik 
MJ, O’Keefe RJ: Smad6 is induced by BMP-2 and modulates chondrocyte 
diff erentiation. J Orthop Res 2003, 21:908-913.
101. Iwai T, Murai J, Yoshikawa H, Tsumaki N: Smad7 inhibits chondrocyte 
diff erentiation at multiple steps during endochondral bone formation and 
down-regulates p38 MAPK pathways. J Biol Chem 2008, 283:27154-27164.
102. Fuentealba LC, Eivers E, Ikeda A, Hurtado C, Kuroda H, Pera EM, De Robertis 
EM. Integrating patterning signals: Wnt/GSK3 regulates the duration of 
the BMP/Smad1 signal. Cell 2007, 131:980-993.
103. Inoue Y, Imamura T. Regulation of TGF-β family signaling by E3 ubiquitin 
ligases. Cancer Sci 2008, 99:2107-2112.
van der Kraan et al. Arthritis Research & Therapy 2010, 12:201 
http://arthritis-research.com/content/12/1/201
doi:10.1186/ar2896
Cite this article as: ven der Kraan PM, et al.: A role for age-related changes in 
TGFβ signaling in aberrant chondrocyte diff erentiation and osteoarthritis. 
Arthritis Research & Therapy 2010, 12:201.
Page 9 of 9
